Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)
- Rebuzzi S. E.
- Signori A.
- Banna G. L.
- Maruzzo M.
- De Giorgi U.
- Pedrazzoli P.
- Sbrana A.
- Zucali P. A.
- Masini C.
- Naglieri E.
- Procopio G.
- Merler S.
- Tomasello L.
- Fratino L.
- Baldessari C.
- Ricotta R.
- Panni S.
- Mollica V.
- Soraru M.
- Santoni M.
- Cortellini A.
- Prati V.
- Soto Parra H. J.
- Stellato M.
- Atzori F.
- Pignata S.
- Messina C.
- Messina M.
- Morelli F.
- Prati G.
- Nole F.
- Vignani F.
- Cavo A.
- Roviello G.
- Pierantoni F.
- Casadei C.
- Bersanelli M.
- Chiellino S.
- Paolieri F.
- Perrino M.
- Brunelli M.
- Iacovelli R.
- Porta C.
- Buti S.
- Fornarini G.
DOIAbstract
Background: Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC) patients achieve a long-term benefit from immunotherapy. Moreover, the identification of prognostic biomarkers is still an unmet clinical need. Methods: This multicenter retrospective study investigated the prognostic role of peripheral-blood inflammatory indices and clinical factors to develop a novel prognostic score in mRCC patients receiving at least second-line nivolumab. The complete blood count before the first cycle of therapy was assessed by calculating neutrophil-to-lymphocyte ratio (NLR), derived NLR (dNLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), systemic inflammation index (SII), and systemic inflammation r...
Add to ORKG